Loading...

ARWR ARROWHEAD PHARMACEUTICALS INC Expansion Plans 8-K Filing

RRWH

RWR

ARROWHEAD PHARMACEUTICALS INC

(ARWR)

2026 8-K

Financial Results Update

Annual Meeting Results

Financial Results

Debt Issuance Details

Equity Offering Announcement

Clinical Trial Results

Financial Results Announcement

FDA Approval Announcement

Patent Dispute Update

Litigation Update

License Agreement

Financial Statements

Financial Statements

Annual Meeting Results

Financial Results

Director Appointment

Financial Results

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Amendment to Board Appointment

Appointment of Director

Financial Results Announcement

Departure of Directors

Agreement for Stock Offering

Dismissal of independent re...

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

External Links:

On January 6, 2026, Arrowhead Pharmaceuticals, Inc. announced interim results from Phase 1/2a trials showing significant weight loss and fat reduction with their drugs ARO-INHBE and ARO-ALK7 in obese patients; ARO-INHBE achieved up to 85% reduction in serum Activin E and a 15.6% reduction in visceral fat.

AI Assistant

ARROWHEAD PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.